Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Tyra Biosciences Inc has a consensus price target of $32.22 based on the ratings of 9 analysts. The high is $37 issued by Wedbush on December 16, 2025. The low is $28 issued by UBS on January 7, 2025. The 3 most-recent analyst ratings were released by Wedbush, Raymond James, and HC Wainwright & Co. on December 16, 2025, September 3, 2025, and August 22, 2025, respectively. With an average price target of $34 between Wedbush, Raymond James, and HC Wainwright & Co., there's an implied 48.02% upside for Tyra Biosciences Inc from these most-recent analyst ratings.
1calculated from analyst ratings
| Get Alert | |||||
|---|---|---|---|---|---|
| Dec 16, 2025 | 61.08% | 3037 | Previous Outperform Current Outperform | Get Alert | |
| Sep 3, 2025 | 52.37% | 35 | Previous Initiates Current Strong Buy | Get Alert | |
| Aug 22, 2025 | 30.61% | 3030 | Previous Buy Current Buy | Get Alert | |
| Jul 1, 2025 | 30.61% | 3030 | Previous Buy Current Buy | Get Alert | |
| May 21, 2025 | 43.67% | 33 | Previous Current Overweight | Get Alert | |
| Mar 31, 2025 | 30.61% | 3030 | Previous Buy Current Buy | Get Alert | |
| Feb 18, 2025 | 30.61% | 3030 | Previous Buy Current Buy | Get Alert | |
| Jan 13, 2025 | 30.61% | 3030 | Previous Buy Current Buy | Get Alert | |
| Jan 7, 2025 | 21.9% | 28 | Previous Initiates Current Buy | Get Alert | |
| Nov 11, 2024 | 30.61% | 3032 | Previous Buy Current Buy | Get Alert | |
| Oct 29, 2024 | 39.31% | 3232 | Previous Buy Current Buy | Get Alert | |
| Oct 28, 2024 | 39.31% | 3032 | Previous Buy Current Buy | Get Alert | |
| Oct 25, 2024 | 21.9% | 2828 | Previous Outperform Current Outperform | Get Alert | |
| Oct 18, 2024 | 34.96% | 2231 | Previous Neutral Current Buy | Get Alert | |
| Oct 7, 2024 | 30.61% | 2530 | Previous Buy Current Buy | Get Alert | |
| Sep 19, 2024 | 43.67% | 2533 | Previous Outperform Current Outperform | Get Alert | |
| Aug 15, 2024 | 43.67% | 33 | Previous Initiates Current Overweight | Get Alert | |
| Aug 8, 2024 | 21.9% | 2828 | Previous Outperform Current Outperform | Get Alert | |
| Aug 8, 2024 | 8.84% | 2528 | Previous Outperform Current Outperform | Get Alert | |
| Jul 3, 2024 | 21.9% | 2828 | Previous Outperform Current Outperform | Get Alert | |
| Jul 3, 2024 | 21.9% | 2828 | Previous Outperform Current Outperform | Get Alert | |
| Jul 3, 2024 | 0.13% | 2323 | Previous Buy Current Buy | Get Alert | |
| Jun 5, 2024 | 0.13% | 2323 | Previous Buy Current Buy | Get Alert | |
| May 13, 2024 | 21.9% | 2528 | Previous Outperform Current Outperform | Get Alert | |
| May 10, 2024 | 21.9% | 2828 | Previous Outperform Current Outperform | Get Alert | |
| May 10, 2024 | 0.13% | 2323 | Previous Buy Current Buy | Get Alert | |
| Mar 21, 2024 | 21.9% | 2828 | Previous Outperform Current Outperform | Get Alert | |
| Mar 20, 2024 | 0.13% | 1923 | Previous Buy Current Buy | Get Alert | |
| Dec 29, 2023 | 17.54% | 2727 | Previous Outperform Current Outperform | Get Alert | |
| Dec 26, 2023 | -17.28% | 1919 | Previous Buy Current Buy | Get Alert | |
| Nov 8, 2023 | -17.28% | 1920 | Previous Buy Current Buy | Get Alert | |
| Aug 11, 2023 | 17.54% | 27 | Previous Outperform Current Outperform | Get Alert | |
| Aug 11, 2023 | -12.93% | 1720 | Previous Buy Current Buy | Get Alert | |
| Aug 1, 2023 | -25.99% | 17 | Previous Buy Current Buy | Get Alert | |
| Jun 30, 2023 | 17.54% | 27 | Previous Initiates Current Outperform | Get Alert | |
| May 8, 2023 | 8.84% | 25 | Previous Current Outperform | Get Alert | |
| May 5, 2023 | -25.99% | 17 | Previous Current Buy | Get Alert | |
| Mar 23, 2023 | -25.99% | 17 | Previous Current Buy | Get Alert | |
| Mar 7, 2023 | -25.99% | 1517 | Previous Current Buy | Get Alert | |
| Mar 2, 2023 | -34.7% | 1215 | Previous Current Buy | Get Alert | |
| Feb 3, 2023 | -25.99% | 17 | Previous Initiates Current Outperform | Get Alert |
The latest price target for Tyra Biosciences (NASDAQ:TYRA) was reported by Wedbush on December 16, 2025. The analyst firm set a price target for $37.00 expecting TYRA to rise to within 12 months (a possible 61.08% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Tyra Biosciences (NASDAQ:TYRA) was provided by Wedbush, and Tyra Biosciences maintained their outperform rating.
The last upgrade for Tyra Biosciences Inc happened on October 18, 2024 when B of A Securities raised their price target to $31. B of A Securities previously had a neutral for Tyra Biosciences Inc.
There is no last downgrade for Tyra Biosciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tyra Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tyra Biosciences was filed on December 16, 2025 so you should expect the next rating to be made available sometime around December 16, 2026.
While ratings are subjective and will change, the latest Tyra Biosciences (TYRA) rating was a maintained with a price target of $30.00 to $37.00. The current price Tyra Biosciences (TYRA) is trading at is $22.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.